OUR VISION A WORLD FREE FROM DEATH AND SUFFERING CAUSED BY FUNGAL DISEASE.

News

Keep up to date with the latest news items from GAFFI.

Should African histoplasmosis be included as a skin Neglected Tropical Disease? Fungal experts think so.

Posted .

January 30th is Global Neglected Tropical Diseases (NTD) Day. This is a worldwide campaign to raise awareness of these often-overlooked conditions. World NTD Day serves as a call to action to secure increased resources for neglected tropical diseases, and crucially facilitate political leadership and ownership of NTD programs from affected countries. The 2021 Neglected Tropic… Read more »

Read more >

Indonesian study reveals missed diagnosis of fungal infections in treated TB patients, with global implications

Posted .

A study of tuberculosis patients in six Jakarta hospitals has revealed up to 13% of them had fungal lung infection  – or aspergillosis – at the end of their treatment. The findings could, warn the research team from Universitas Indonesia and The University of Manchester, have implications globally wherever TB is found. The study tracked… Read more »

Read more >

Less than 15% of African countries have access to life-saving diagnostic for common AIDS-defining respiratory illnesses.

Posted .

On World AIDS Day, experts call for global commitment towards the purchasing of diagnostic tests for Pneumocystis pneumonia (PCP), a respiratory fungal infection responsible for a high proportion of deaths among HIV positive children and adults in Africa. A recent survey conducted by GAFFI assessing the availability of WHO listed essential diagnostics for fungal diseases… Read more »

Read more >

Antifungal echinocandins added to the WHO’s Essential Medicines List

Posted .

Echinocandin antifungal drugs are the ‘workhorses’ of antifungal therapy in hospitals. The WHO has endorsed their importance by adding them to the 2021 Essential Medicines List for low and middle countries, for both adults and children.    Initially launched in 2002 in Japan and USA, micafungin (Astellas) and caspofungin (Merck) were the first to market… Read more »

Read more >

GAFFI IS NOW LOOKING FOR NEW BOARD MEMBERS

Posted .

GAFFI is committed to strengthening our board based on equality, diversity and inclusion of members with background from our geographical focus areas. We would appreciate, in our first step, to receive applications from female applicants with cultural background from outside Europe. Today we have a strong medical (fungal) expertise, management, marketing and HR are other… Read more »

Read more >

Climbing antifungal drug resistance in South-East Asia ‘worrying’

Posted .

Researchers say it is possible that increased agricultural fungicide use may be contributing to gradual azole fungal drug resistance in Aspergillus in South East Asia and around the world. Azole antifungals are the most important group for treating many fungal diseases. Resistance to azole in Aspergillus is much more prevalent in South East Asia than… Read more »

Read more >

Covid-19 reverses gains in survival rates in HIV patients

Posted .

Deaths rose from 16.6% to 27.3% during COVID, nearly 1 in 9 additional deaths, in Guatemala’s leading HIV centre in 2020 compared with 2019. Just published in the International Journal of Infectious Diseases – Narda Medina and colleagues charted the provision of HIV care in Guatemala and how the global pandemic has affected diagnosis and… Read more »

Read more >